Biktarvy and oncology sales help Gilead to offset Veklury decline

28 April 2023
gilead-large

As with many biopharma firms, Gilead Sciences (Nasdaq: GILD) reported a drop in first-quarter revenue this year due to a decline in sales of a COVID-19 treatment.

The US biotech company’s overall quarterly sales figure fell by 3.6% to $6.4 billion, although this was ahead of analysts’ expectations of $6.31 billion. Product sales excluding the COVID-19 drug Veklury (remdesivir) rose by 15% to $5.7 billion.

Diluted earnings per share came in at $1.37, worse than the $1.53 expected by analysts and 35% down on the first quarter of 2022.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology